Breast Cancer Chemoprevention: Current Challenges and a Look Toward the Future
- 1 June 2002
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 3 (2) , 113-124
- https://doi.org/10.3816/cbc.2002.n.016
Abstract
No abstract availableKeywords
This publication has 133 references indexed in Scilit:
- Role of the Insulin-Like Growth Factor Family in Cancer Development and ProgressionJNCI Journal of the National Cancer Institute, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: Results of the Papanicolaou Society of Cytopathology studyDiagnostic Cytopathology, 1998
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- Hormone replacement after breast cancerThe Lancet, 1993
- Development of breast cancer chemopreventive drugsJournal of Cellular Biochemistry, 1993
- Tamoxifen reduces serum insulin-like growth factor I (IGF-I)Breast Cancer Research and Treatment, 1992
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levelsLife Sciences, 1983